Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ibezapolstat

Phase 2Small molecule

AAcurx Pharmaceuticals Inc.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridium Difficile Infection RecurrenceRecruiting

Clostridium Difficile Infection RecurrencePhase 2

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Clostridium Difficile Infection Recurrence

NCT07513285

Clinical

Trials by Indication[1]

Clostridioides difficile Infection1 trial

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Completed·AAcurx Pharmaceuticals Inc.·Phase 2·NCT04247542·53 enrolled

Clostridium Difficile Infection Recurrence1 trial

A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)

Recruiting·AAcurx Pharmaceuticals Inc.·Phase 2·NCT07513285·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ibezapolstat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ibezapolstat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ibezapolstat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acurx Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAcurx Pharmaceuticals Inc.

Related News